Immunologic aspects of cancer chemotherapy.
D000818:Animals; D001500:BCG Vaccine; D003520:Cyclophosphamide / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy; D007978:Levamisole / Q000494:pharmacology; D015122:Mercaptopurine / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011425:Propionibacterium acnes; D014748:Vinca Alkaloids / Q000494:pharmacology
D001500:BCG Vaccine; D007166:Immunosuppressive Agents; D014748:Vinca Alkaloids; D003561:Cytarabine; D007978:Levamisole; D004317:Doxorubicin; D003520:Cyclophosphamide; D015122:Mercaptopurine; D005472:Fluorouracil; D008727:Methotrexate; D003630:Daunorubicin